Abstract 112P
Background
Biliary tract cancers (BTC), including cholangiocarcinomas (CCA) are rare but aggressive cancers primarily affecting patients (pts) >70 years (median age at diagnosis : 72-78 years). However, there has been a rise in the incidence of CCA among younger individuals (<50 years). This study aimed to investigate clinical, genomic and transcriptomic characteristics and outcomes of young-onset BTC/CCA (YOC) pts.
Methods
We identified all consecutive patients with histologically confirmed CCA treated at Gustave Roussy (France) between 2015 and 2021 as part of the ACABI-PRONOBIL multicenter cohort study. Clinical data were extracted from medical records. Genomic data were obtained through in-house or Foundation Medicine® panels. Transcriptomic analyses were performed for 58 pts (13 YOC) at metastatic diagnosis.
Results
Of the 546 pts with CCA, 92 (16.8%) had YOC (median age, 42 years; range, 27-50). Median overall survival (mOS) from 1st line therapy was 22.7 months (mo) (95%CI: 18.3-27.6) for YOC patients vs 19.2 mo (95%CI: 18.0-22.0) for non-YOC patients (p=0.14). Molecular profiling was more often performed for YOC pts (68% vs 55%, p<0.05). Rates of actionable molecular alterations (IDH1/2, BRAF, FGFR2, NTRK, HER2, MSI) and targeted therapies administration did not differ between YOC and non-YOC pts. CDKN2A alterations were less frequent in YOC than in non-YOC pts (12.6% vs 25.2%, p<0.05). Differentially expressed genes between YOC and non-YOC pts with Gene Set Enrichment Analysis were mostly genes involved in immunity and WNT signaling pathways. Table: 112P
| Genomic characteristics | Age <=50 n=92 | age>50 n=454[BA1] | |||
| n | % | n | % | ||
| Molecular profile available | No | 29 | 32% | 204 | 45% |
| Yes | 63 | 68% | 250 | 55% | |
| Actionable alteration | No | 41 | 65% | 141 | 56% |
| Yes | 22 | 35% | 109 | 44% | |
| Main actionable alterations | No alteration | 11 | 17% | 43 | 17% |
| Mutation IDH1/2 | 8 | 13% | 40 | 16% | |
| Fusion FGFR 1-4 | 8 | 13% | 21 | 8% | |
| Amplification HER2 | 3 | 5% | 15 | 6% | |
| Mutation BRAF V600E | 0 | 0% | 10 | 4% | |
| EGFR | 2 | 3% | 7 | 3% | |
| Fusion NTRK | 6 | 10% | 11 | 4% | |
| Mutation KRAS G12C | 1 | 2% | 3 | 1% | |
| Other relevant alterations | KRAS | 16 | 25% | 40 | 16% |
| TP53 | 25 | 40% | 91 | 36% | |
| CDKN2A/B | 8 | 13% | 63 | 25% | |
| MMR status (n=199) | dMMR/MSI | 0 | 0% | 11 | 7% |
| pMMR/MSS | 47 | 100% | 141 | 93% | |
| Targeted therapies administration | No | 41 | 65% | 141 | 56% |
| Yes | 22 | 35% | 109 | 44% |
Conclusions
Although tending to have a more advanced disease at diagnosis, YOC patients had OS similar to that of non-YOC pts, and no more actionable molecular alterations. Our findings suggest that the biological mechanisms driving CCA in YOC patients may be different from those in older patients and warrant further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Gercor.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Presenter: Irene Moreno
Session: Poster session 17
680P - First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Presenter: Kathleen Moore
Session: Poster session 17
681P - First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 17
683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Presenter: Yongqiang Shan
Session: Poster session 17
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Presenter: Jin Li
Session: Poster session 17
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Presenter: Erwei Song
Session: Poster session 17
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Presenter: Jiong Wu
Session: Poster session 17
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17
688P - Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Presenter: Oladipo Idowu
Session: Poster session 17
689P - DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Presenter: Omkar Marathe
Session: Poster session 17